These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
601 related items for PubMed ID: 12912810
1. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Haider A, Lee I, Grabarek J, Darzynkiewicz Z, Ferreri NR. Circulation; 2003 Aug 26; 108(8):1015-21. PubMed ID: 12912810 [Abstract] [Full Text] [Related]
5. Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Kim CH, Moon SK. Arch Biochem Biophys; 2005 Mar 15; 435(2):264-72. PubMed ID: 15708369 [Abstract] [Full Text] [Related]
6. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells. Shiokoshi T, Ohsaki Y, Kawabe J, Fujino T, Kikuchi K. J Hypertens; 2002 Mar 15; 20(3):455-61. PubMed ID: 11875313 [Abstract] [Full Text] [Related]
10. The role of selective nitric oxide synthase inhibitor on nitric oxide and PGE2 levels in refractory hemorrhagic-shocked rats. Md S, Moochhala SM, Siew Yang KL, Lu J, Anuar F, Mok P, Ng KC. J Surg Res; 2005 Feb 15; 123(2):206-14. PubMed ID: 15680380 [Abstract] [Full Text] [Related]
11. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C. Circ Res; 2003 Sep 05; 93(5):406-13. PubMed ID: 12919948 [Abstract] [Full Text] [Related]
12. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Niederberger E, Manderscheid C, Grösch S, Schmidt H, Ehnert C, Geisslinger G. Biochem Pharmacol; 2004 Jul 15; 68(2):341-50. PubMed ID: 15194006 [Abstract] [Full Text] [Related]
13. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Hu KQ, Yu CH, Mineyama Y, McCracken JD, Hillebrand DJ, Hasan M. Int J Oncol; 2003 Apr 15; 22(4):757-63. PubMed ID: 12632065 [Abstract] [Full Text] [Related]
14. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Circ Res; 2000 Apr 28; 86(8):906-14. PubMed ID: 10785514 [Abstract] [Full Text] [Related]
15. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases. Touyz RM, Yao G. J Cell Physiol; 2003 Dec 28; 197(3):326-35. PubMed ID: 14566962 [Abstract] [Full Text] [Related]
16. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cahlin C, Gelin J, Delbro D, Lönnroth C, Doi C, Lundholm K. Cancer Res; 2000 Mar 15; 60(6):1742-9. PubMed ID: 10749148 [Abstract] [Full Text] [Related]
17. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Boyle JJ, Weissberg PL, Bennett MR. Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1553-8. PubMed ID: 12869351 [Abstract] [Full Text] [Related]
18. Regulation of cyclooxygenase-2 by nitric oxide in activated hepatic macrophages during acute endotoxemia. Ahmad N, Chen LC, Gordon MA, Laskin JD, Laskin DL. J Leukoc Biol; 2002 Jun 01; 71(6):1005-11. PubMed ID: 12050186 [Abstract] [Full Text] [Related]